Ocugen Inc

NASDAQ:OCGN   3:28:22 PM EDT
6.45
0.00 (-0.08%)
Products

Ocugen, Inc. Announces Submission Of Investigational New Drug Application With U.S. FDA To Initiate A Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate Ocu400 (Aav-Nr2e3) To Treat Inher

Published: 11/08/2021 14:42 GMT
Ocugen Inc (OCGN) - Ocugen, Inc. Announces Submission of Investigational New Drug Application With U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate Ocu400 (aav-nr2e3) to Treat Inherited Retinal Degeneration.
Ocugen Inc - Plans to Follow Phase 1/2 Trial With a Phase 3 Study, Upon Further Review of Data.